Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
4.950
-0.150 (-2.94%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nuvectis Pharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 14, 2024
Via
Benzinga
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
November 14, 2024
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.
Via
Benzinga
S&P 500 Moves Lower; US Crude Oil Inventories Increase
November 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Dow Falls Over 100 Points; US Producer Prices Rise In October
November 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Edge Lower; Cisco Earnings Top Views
November 14, 2024
Via
Benzinga
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort
November 14, 2024
Via
AB Newswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
November 14, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
October 28, 2024
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).
Via
News Direct
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
October 28, 2024
From
PESG Research
Via
Business Wire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
October 23, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 16, 2024
Via
Benzinga
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 07, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.
Via
News Direct
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
September 16, 2024
Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data
Via
News Direct
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
September 16, 2024
From
PESG Research
Via
Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
August 29, 2024
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
Via
News Direct
Exposures
Product Safety
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
August 15, 2024
Via
AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
July 18, 2024
Via
AB Newswire
Precision Medicine M&A is Transforming the Future of the Biotech Industry
June 17, 2024
Via
AB Newswire
7 Penny Biotech Stocks to Triple Your Investment
May 28, 2024
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
Via
InvestorPlace
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
May 07, 2024
NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
April 08, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 19, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 15, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 14, 2024
Via
Benzinga
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
March 14, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
March 05, 2024
NVCT stock results show that Nuvectis Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.